Exploring CAR T-Cell Therapy During the COVID-19 Pandemic: A Closer Look at Real-World Data

This OncLive^® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T cells.

The following objectives will be reviewed:

• Review of available therapies, indications, and eligible patient populations·
• Examine real-world data associated with available CAR T-cell therapies
• Improving access and overcoming barriers to CAR T-cell therapy

We feature a panel of leading experts to discuss important topics and considerations surrounding CAR T-cell therapies and the patient populations impacted during this time.

Faculty:

Loretta J. Nastoupil, MD
Associate Professor
Section Chief, Indolent Lymphoma
Section Chef, New Drug Development
Department Lymphoma/Myeloma
UT MD Anderson Cancer Center

Ahmed Galal, MD, FRACP, MSc
Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
Duke School of Medicine

Matthew Lunning, DO
Associate Professor, Internal Medicine
Medical Director, Lymphoma Research
Division of Oncology & Hematology
University of Nebraska Medical Center

Sponsored by: KITE